CONGRESS ABSTRACT

Since the publication of the 2019 ESC/EAS Guidelines and their last update in 2025 (1) for the management of dyslipidemias, there is a progressive widespread use of statins because of their impact in reducing the incidence of cardiovascular disease. Statins are generally safe and tolerable. A mild myalgia is…

Background and objectives: People living with HIV (PLWH) face an increased cardiovascular (CV) risk due to the interaction of traditional risk factors, chronic inflammation and cumulative antiretroviral therapy (ART) adverse metabolic effects. However, standard risk models often underestimate this burden, limiting effective prevention. This study evaluates LDL cholesterol target…

Bempedoic acid were indicated to be able to reduce the hypercholesterolemia add on to statin and ezetimibe therapy. We investigated the effect of the same treatment in carotid atherosclerosis after a follow up of 6 months. Methods A continuous series of 22 patients were enrolled in a prospective analysis….

Background and aims Despite LDL cholesterol (LDL-C) is a well-established modifiable risk factor in patients in secondary cardiovascular prevention, only 30% of them reach the LDL target <55 mg/dl. In our hospital, a protocol of intensive lipid-lowering therapy (LLT) is applied in patients with coronary artery disease (CAD). The…

Background. Numerous scientific evidence demonstrate that the rapid achievement of optimal LDL cholesterol levels after an acute coronary syndrome is associated with improved outcomes. The aim of this retrospective analysis is to describe the use of lipid-lowering therapy in this clinical setting and the results obtained. In particular, we…

Background : Acute coronary syndromes (ACS) are characterized by partial or total occlusion of one or more coronary vessels caused by atherosclerosis. Dyslipidemia plays a major role in atheroma formation. Objectives : We collected three-month follow-up data to assess the outcomes of the therapy prescribed at hospital discharge. We…

Background: Statins are a cornerstone of LDL-cholesterol lowering, but perceived intolerance—especially muscle complaints—remains a leading cause of discontinuation and loss of cardiovascular protection. Aim: To review evidence that contextual mechanisms (nocebo/drucebo) account for a substantial share of symptoms attributed to statins, and to translate this evidence into pragmatic clinical…